Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan
Journal of Antimicrobial Chemotherapy · 01.08.2024 · 79 (8) · 1843-1855
DOI: 10.1093/jac/dkae168 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 06.06.2024. Verfasst von Ryota Hase und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Microbial Sensitivity Tests. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Shionogi & Co., Ltd, NIH HHS.
Abstract (Originalsprache)
Background
Stenotrophomonas maltophilia is a carbapenem-resistant Gram-negative pathogen increasingly responsible for difficult-to-treat nosocomial infections.
Objectives
To describe the contemporary clinical characteristics and genome epidemiology of patients colonized or infected by S. maltophilia in a multicentre, prospective cohort.
Methods
All patients with a clinical culture growing S. maltophilia were enrolled at six tertiary hospitals across Japan between April 2019 and March 2022. The clinical characteristics, outcomes, antimicrobial susceptibility and genomic epidemiology of cases with S. maltophilia were investigated.
Results
In total, 78 patients were included representing 34 infection and 44 colonization cases. The median age was 72.5 years (IQR, 61–78), and males accounted for 53 cases (68%). The most common comorbidity was localized solid malignancy (39%). Nearly half of the patients (44%) were immunosuppressed, with antineoplastic chemotherapy accounting for 31%. The respiratory tract was the most common site of colonization (86%), whereas bacteraemia accounted for most infection cases (56%). The 30 day all-cause mortality rate was 21%, which was significantly higher in infection cases than colonization cases (35% versus 9%; adjusted HR, 3.81; 95% CI, 1.22–11.96). Susceptibility rates to ceftazidime, levofloxacin, minocycline and sulfamethoxazole/trimethoprim were 14%, 65%, 87% and 100%, respectively. The percentage of infection ranged from 13% in the unclassified group to 86% in genomic group 6A. The percentage of non-susceptibility to ceftazidime ranged from 33% in genomic group C to 100% in genomic groups 6 and 7 and genomic group geniculate.
Conclusions
In this contemporary multicentre cohort, S. maltophilia primarily colonized the respiratory tract, whereas patients with bacteraemia had the highest the mortality from this pathogen. Sulfamethoxazole/trimethoprim remained consistently active, but susceptibility to levofloxacin was relatively low. The proportions of cases representing infection and susceptibility to ceftazidime differed significantly based on genomic groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
- Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Chiba, Japan.
- Division of Infectious Diseases, Aichi Cancer Center, Nagoya, Aichi, Japan.
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
- Department of Biostatistics and Bioinformatics, Interfaculty Initiative in Information Studies, The University of Tokyo, Bunkyo, Tokyo, Japan.
ORCID-Profile: Ryota Hase, Naoya Itoh, Kayoko Hayakawa, Yasufumi Matsumura, David van Duin, Norio Ohmagari, Yohei Doi
Förderung
- NIAID NIH HHS
- Shionogi & Co., Ltd
- NIH HHS
- NCGM Intramural Research Fund
- Japan Society for the Promotion of Science
- National Institutes of Health
Zitieren
APA
Hase, R., Sakurai, A., Suzuki, M., Itoh, N., Hayakawa, K., Uemura, K., Matsumura, Y., Kato, H., Ishihara, T., van Duin, D., Ohmagari, N., Doi, Y., & Saito, S. (2024). Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan. Journal of Antimicrobial Chemotherapy, 79(8), 1843-1855. https://doi.org/10.1093/jac/dkae168
Vancouver
Hase R, Sakurai A, Suzuki M, Itoh N, Hayakawa K, Uemura K, et al. Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan. Journal of Antimicrobial Chemotherapy. 2024;79(8):1843-1855. doi:10.1093/jac/dkae168
BibTeX
@article{Hase2024,
author = {Hase, Ryota and Sakurai, Aki and Suzuki, Masahiro and Itoh, Naoya and Hayakawa, Kayoko and Uemura, Kohei and Matsumura, Yasufumi and Kato, Hideaki and Ishihara, Takuma and van Duin, David and Ohmagari, Norio and Doi, Yohei and Saito, Sho},
title = {Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {8},
pages = {1843--1855},
doi = {10.1093/jac/dkae168}
}
EUVIMED